Bristol-Myers Squibb (NYSE: BMY) reported Q3 EPS of $1.99, $0.17 better than the analyst estimate of $1.82. Revenue for the quarter came in at $11.22 billion versus the consensus estimate of $11.15 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2022 revenue of $46 billion, versus the consensus of $46 billion.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.